Despite advances in understanding the molecular pathogenesis of multiple myeloma and
promising new therapies, almost all patients eventually relapse with resistant disease. There …

Introduction: Heat-shock protein 90 (Hsp90) is a validated novel anticancer target with
unique features. As a molecular chaperone, Hsp90 is implicated in maintaining the …

Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in
cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic …

Background: Although inhibitors of histone deacetylase inhibitors (HDACis) in combination
with genotoxins potentiate apoptosis, the role of proteases other than caspases in this …

We studied the role of histone deacetylase inhibitors in Waldenstrom's macroglobulinemia
(WM). Gene expression profiling of bone marrow CD19+ cells from 30 patients and 10 …

Purpose: Therapeutic strategies that target insulin-like growth factor 1 receptor (IGF-1R) hold
promise in a wide variety of cancers including multiple myeloma (MM). In this study, we …

Histone deacetylases (HDACs) are aberrantly expressed, and inhibitors of HDACs induce
apoptosis in lymphoplasmacytic cells (LPCs) in Waldenström macroglobulinemia (WM). The …

The focus of this thesis was to evaluate the mechanisms whereby myeloma cells develop
intrinsic resistance with a focus on resistance in the context of bortezomib treatment. The …

Beim multiplen Myelom handelt es sich um eine Neoplasie terminal differenzierter B-
Lymphozyten, die durch eine diffuse oder multilokuläre Infiltration des Knochenmarks mit …

Multiple Myeloma (MM) is a clonal expansion of plasma cells. MM is characterized by
proliferation of malignant clones producing defective monoclonal immunoglobulins in the …